GLPBio

E3 Ligase Ligand-Linker Conjugate

Read More about this category

E3 Ligase Ligand-Linker Conjugate, which is one part of Proteolysis Targeting Chimeric Molecules (PROTACs), incorporates a ligand for the E3 ubiquitin ligase and a linker. After linked to the ligand for target protein (such as JQ1 for BRD4 protein, Molibresib for BET protein), those conjugates can be used for constituting PROTACs that targetprotein for ubiquitination and degradation. Currently, several PROTACs have been found to show good biological activity by specifically targeting BET, estrogen receptor (ER), androgen receptor, etc.MedChemExpress (MCE) offers a wide range of high quality E3 Ligase Ligand-Linker Conjugates including von Hippel-Lindau (VHL) ligands, MDM2 ligands, Cereblon (CRBN) ligands and cIAP1 ligands conjugating with different linkers (PEGs, Alkyl-Chain, Alkyl/ether, etc.). It’s convenient and time-saving for designing and synthesizinga wide variety of novel PROTACs (ARV-825, dBET1,MT-802, etc.), which can expand the application of PROTACs in the treatment of cancer, autoimmunity, inflammation and other diseases.

Products Related to E3 Ligase Ligand-Linker Conjugate(201)

  • GC35955 structure
    GC35955E3 ligase Ligand-Linker Conjugates 48
    Purity: >98%
  • GC35956 structure
    GC35956E3 ligase Ligand-Linker Conjugates 49
    CAS: 2351103-63-2
    Purity: >98%

    E3 ligase Ligand-Linker Conjugates 49 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

  • GC35957 structure
    GC35957E3 ligase Ligand-Linker Conjugates 50
    Purity: >98%
  • GC35958 structure
    GC35958E3 ligase Ligand-Linker Conjugates 51
    Purity: >98%
  • GC38095 structure
    GC38095Thalidomide-O-amido-C3-NH2 (TFA)
    CAS: 2022182-58-5
    Purity: >98.00%

    Thalidomide-O-amido-C3-NH2 (TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

  • GC38381 structure
    GC38381Pomalidomide-C2-NH2 hydrochloride
    CAS: 2305369-00-8
    Purity: >98%

    Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

  • GC38808 structure
    GC38808Lenalidomide-propargyl-C2-NH2 hydrochloride
    CAS: 2489242-23-9
    Purity: >99.00%

    Lenalidomide-propargyl-C2-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Lenalidomide-propargyl-C2-NH2 hydrochloride can be used to design the PROTAC MD-224.

  • GC38861 structure
    GC38861Thalidomide-O-PEG2-propargyl
    CAS: 2098487-52-4
    Purity: >98%

    Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

  • GC38870 structure
    GC38870VH032-PEG3-acetylene
    CAS: 2098799-80-3
    Purity: >98%

    VH032-PEG3-acetylene is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

  • GC38949 structure
    GC38949Thalidomide-NH-PEG2-C2-NH2 TFA
    CAS: 2097509-36-7
    Purity: >98.50%

    Thalidomide-NH-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

  • GC39171 structure
    GC39171Pomalidomide-amido-C1-Br
    CAS: 2351106-38-0
    Purity: >98%

    Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1. PROTAC B-Raf degrader 1 has anti-cancer activity.

  • GC39513 structure
    GC39513Thalidomide-NH-C6-NH2 TFA
    CAS: 2093386-51-5
    Purity: >99.50%

    Thalidomide-NH-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

  • GC50463 structure
    GC50463Thalidomide 4'-oxyacetamide-PEG4-amine
    CAS: 2245697-85-0
    Purity: >98%

    Thalidomide 4'-oxyacetamide-PEG4-amine, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

  • GC50466 structure
    GC50466A 410099.1, amine
    CAS: 2374122-37-7
    Purity: >98%

    A 410099.1, amine is afunctionalizedIAP ligand and can be used for the synthesis of PROTACs, such as PROTACs targeting BTK (PROTACs 4 and 5).

  • GC50528 structure
    GC50528Thalidomide 4'-ether-alkylC6-amine
    CAS: 2245697-88-3
    Purity: >98.50%

    Thalidomide 4'-ether-alkylC6-amine is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET.

  • GC50545 structure
    GC50545Pomalidomide 4'-PEG3-acid
    CAS: 2138440-82-9
    Purity: >98.50%

    Pomalidomide 4'-PEG3-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

  • GC50583 structure
    GC50583Thalidomide 4'-ether-alkylC2-amine
    CAS: 2341840-99-9
    Purity: >98%

    Thalidomide 4'-ether-alkylC2-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

  • GC50584 structure
    GC50584VH 032 amide-alkylC2-amine
    CAS: 2341796-73-2
    Purity: >98.50%

    VH 032 amide-alkylC2-amine incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-OH can be used in the synthesis of a series of PROTACs.

  • GC50585 structure
    GC50585VH 032 amide-alkylC6-amine
    CAS: 2341796-77-6
    Purity: >98%

    VH 032 amide-alkylC6-amine (VH032-C6-NH2 dihydrochloride) is a synthesizedE3 ligase ligand-linker conjugatethat incorporates the VH032 based VHL ligand and a linker used forAKTPROTAC degrader.

  • GC50592 structure
    GC50592VH 032 amide-alkylC10-amine
    CAS: 2341796-75-4
    Purity: >98%

    VH 032 amide-alkylC10-amine (VH032-C10-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.

  • GC50620 structure
    GC50620Thalidomide 4'-oxyacetamide-alkylC2-amine
    CAS: 2341841-02-7
    Purity: >98%

    Thalidomide 4'-oxyacetamide-alkylC2-amine incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Thalidomide 4'-oxyacetamide-alkylC2-amine can be used to design the PROTACs.

  • GC50622 structure
    GC50622Thalidomide 4'-ether-PEG5-amine
    CAS: 2341841-01-6
    Purity: >98%

    Cereblon ligand with PEG linker and terminal amine for onward chemistry

  • GC50626 structure
    GC50626Thalidomide 4'-oxyacetamide-PEG1-amine
    CAS: 2204226-02-6
    Purity: >98.50%

    Thalidomide 4'-oxyacetamide-PEG1-amine, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

  • GC50657 structure
    GC50657Thalidomide 4'-ether-alkylC2-acid
    CAS: 2369068-42-6
    Purity: >95.00%

    Thalidomide 4'-ether-alkylC2-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.